In vitro amplification of the Bcr‐Abl cDNA has been widely used to assess for the presence
of minimal residual disease in patients with chronic myelogenous leukaemia (CML) …

We sought evidence of BCR/ABL transcripts in the peripheral blood of nine CML patients in
complete clinical and cytogenetic remission after treatment by bone marrow transplantation …

BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

We have developed a rapid real‐time quantitative PCR method for measuring BCR‐ABL
mRNA levels in peripheral blood in chronic myeloid leukaemia (CML). The technique was …

A substantial minority of patients with chronic myeloid leukaemia (CML) achieve a complete
response to treatment with interferon‐α (IFN‐α), defined as the disappearance of …

The degree of tumor load reduction after therapy, which is determined by the degrees of
cytoreduction and cytogenetic response, is an important prognostic factor for patients with …

We measured using a competitive quantitative polymerase chain reaction-capillary
electrophoresis (PCR-CE)-based assay, the levels of bcr-abl transcripts in 44 patients with …

We present the results of a novel method developed for evaluation of in situ amplification, a
molecular genetic method at the cellular level. Reverse transcription polymerase chain …

Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) is used to confirm the
diagnosis and to monitor residual disease. Quantitative techniques are required to predict …

Methods of minimal residual disease (MRD) detection in chronic myelogenous leukemia
(CML) include chromosome analysis, reverse transcriptase polymerase chain reaction (RT …